In contrast, Eli Lilly (NYSE: LLY) and Hims & Hers Health (NYSE: HIMS) both jumped on today's news. They rose 2.7% and 7%, ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...

Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major ...

Eli Lilly and Novo Nordisk have scored big wins from the FDA in recent months, as the agency cracks down on copycat versions of their GLP-1 blockbusters. Now, as the battle with compound GLP-1s comes ...

With Eli Lilly’s Mounjaro entering India, the weight-loss drug race is on. But with steep prices and generics on the way, how ...

A single-dose vial of Mounjaro costs Rs. 3,500 for 2.5 mg or Rs. 4,375 for 5 mg. On a typical weekly dose, that adds up to ...

Zerodha’s Nithin Kamath sparks debate on Ozempic, Mounjaro & their game-changing impact on obesity, addiction & industries. Is India ready for this shift?

While medications provide temporary weight-loss solutions, experts stress lifestyle changes as the most effective way to ...

Kamath flagged that most of the world — including India — still doesn’t fully understand the long-term impact of these drugs.

A United States Senator has disclosed a series of stock trades, some raising questions about possible insider information use ...

Berenberg Bank analyst Kerry Holford maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.